Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA September 600x60px
Document › Details

KineMed Inc.. (1/13/14). "Press Release: KineMed Announces Agreement with EMD Serono to Identify Protein and Lipid Biomarkers for Multiple Sclerosis". Emeryville, CA.

Organisations Organisation KineMed Inc.
  Organisation 2 EMD Serono Inc.
  Group Merck (DE) (Group)
Products Product biomarker discovery services
  Product 2 mass spectrometry services (MS services)
Index term Index term Merck (DE)–KineMed: biomarker discovery services, 201401– supply service applying mass spec to identify protein + lipid multiple sclerose markers
Persons Person Enns, Timothy L. (KineMed 201401– Chief Investor + Media Relations Officer before Astex/SuperGen)
  Person 2 Kiron, Ravi (KineMed 201401 CBO)
     


KineMed, Inc. today announced an agreement with EMD Serono to apply KineMed's mass spectrometric Dynamic Proteomics and lipids platforms to the discovery of protein and lipid biomarkers for multiple sclerosis.

Myelin breakdown and synthesis is a fundamental process underlying progression and resolution of demyelinating disorders such as multiple sclerosis (MS). Sensitive biomarkers of myelin synthesis are necessary for monitoring the in vivo response to candidate remyelinating agents. KineMed's proprietary technology platform will be used to discover biomarkers that will allow EMD Serono to track and monitor rates of myelin breakdown and repair in the living brain. The synthesis of several myelin lipids and protein components, including cholesterol, galactocerebroside and phospholipids, as well as major myelin proteins, will be measured during periods of demyelination and remyelination in animal models. These measurements will be made by use of KineMed's proprietary Dynamic Proteomics and lipid synthesis technologies. This study will also utilize KineMed's recently developed non-invasive translational marker of brain cholesterol synthesis, which measures synthesis of brain-specific 24-hydroxy-cholesterol in the blood to better understand temporal changes in brain cholesterol synthesis relevant to MS.


About KineMed, Inc.

KineMed is a commercial-stage company focused on applying its proprietary biomarker platform technology to drug development, prescription and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests.

KineMed's diagnostic biomarker tests directly measure the biological processes that cause disease by revealing the flux, or rate of production and destruction, over a period of time, of the key molecules involved in these biological processes. KineMed believes that measuring molecular fluxes can provide interpretable information that may be predictive for clinically meaningful endpoints for a particular patient and are designed to reveal personalized information for a patient that can guide healthcare decisions. As a result, KineMed believes KineMed's biomarkers have the potential to have a transformative effect on healthcare by providing information that can be used to make drug development more efficient, and guide healthcare decisions by physicians and wellness decisions by consumers. Building on a legacy of collaborative relationships and experience performing biomarker tests in human disease research and drug development settings, KineMed is currently focused on commercializing biomarker tests in six areas: muscle biology, fibrotic diseases, neurodegenerative diseases, cardiometabolic diseases, skincare and cancer. KineMed's muscle biology program represents its most advanced initiative that focuses its proprietary technology on a long-standing need in medicine and wellness management.

For more information about KineMed, please visit: www.kinemed.com


Contact:


KineMed, Inc.
Timothy L Enns
Chief Investor and Media Relations Officer
Tel: 510-655-6525 ext. 136
Cell: 925-719-2143
tenns@kinemed.com

KineMed, Inc.
Ravi Kiron, Ph.D., MBA
Chief Business Officer
Tel: 510-655-6525 ext. 105
Cell: 650-224-3826
rkiron@kinemed.com

   
Record changed: 2016-03-19

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for KineMed Inc.


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px